First-line fulvestrant vs. anastrozole in hormone receptor-positive advanced breast cancer: insights from the final FALCON trial results
Permalink : https://ousar.lib.okayama-u.ac.jp/71192
| フルテキストURL | |
| 著者 |
Takahashi, Yuko
Department of Breast and Endocrine Surgery, Okayama University Hospital
Nakamoto, Shogo
Department of Breast and Endocrine Surgery, Okayama University Hospital
Tanioka, Maki
Department of Breast and Endocrine Surgery, Okayama University Hospital
Shien, Tadahiko
Department of Breast and Endocrine Surgery, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
|
| キーワード | Selective estrogen receptor degrader (SERD)
aromatase inhibitor (AI)
endocrine therapy (ET)
hormone receptor-positive (HR+)
advanced breast cancer
|
| 発行日 | 2026-04
|
| 出版物タイトル |
Chinese Clinical Oncology
|
| 巻 | 15巻
|
| 号 | 2号
|
| 出版者 | AME Publishing Company
|
| 開始ページ | 22
|
| ISSN | 2304-3865
|
| 資料タイプ |
学術雑誌論文
|
| 言語 |
英語
|
| OAI-PMH Set |
岡山大学
|
| 著作権者 | © AME Publishing Company.
|
| 論文のバージョン | publisher
|
| PubMed ID | |
| DOI | |
| Web of Science KeyUT | |
| 関連URL | isVersionOf https://doi.org/10.21037/cco-2025-1-175
|
| ライセンス | https://creativecommons.org/licenses/by-nc-nd/4.0/
|
| Citation | Takahashi Y, Nakamoto S, Tanioka M, Shien T. First-line fulvestrant vs. anastrozole in hormone receptor-positive advanced breast cancer: insights from the final FALCON trial results. Chin Clin Oncol 2026;15(2):22. doi: 10.21037/cco-2025-1-175
|
